NCT05702021 Implementing Contingency Management for Stimulant Use in Specialty Addiction Treatment Organizations
| NCT ID | NCT05702021 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northwestern University |
| Condition | Stimulant Use (Diagnosis) |
| Study Type | INTERVENTIONAL |
| Enrollment | 76 participants |
| Start Date | 2023-06-07 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 76 participants in total. It began in 2023-06-07 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Stimulants constitute a new and deadly fourth wave of the opioid epidemic. Contingency management is the most effective intervention for stimulant use and is an evidence-based adjunct to medication for opioid use disorder. Yet, uptake of contingency management in opioid treatment programs that provide medication for opioid use disorder remains low; in fact, access to contingency management is arguably one of the greatest research-to-practice gaps in the addiction treatment services field. The goal of this study is to conduct a type III hybrid effectiveness-implementation trial to evaluate a multi-level implementation strategy, the Science of Service Laboratory, to install contingency management for stimulant use in opioid treatment programs. The Science of Service Laboratory has three core components: didactic training, performance feedback, and external facilitation. Utilizing a stepped wedge design, a cohort of public sector addiction specialty treatment programs will be randomized to receive Science of Service Laboratory across four cohorts. Each of the programs will provide de-identified electronic medical record data from all available patient charts on contingency management delivery and patient outcomes. Staff from each program will provide feedback on contextual determinants influencing implementation. This study will rigorously evaluate whether a multi-level implementation strategy developed by one of the longest-standing national intermediary purveyor organizations-the SAMHSA Technology Transfer Centers, will improve both implementation and patient outcomes.
Eligibility Criteria
* Opioid Treatment Program Counselors: * Inclusion criteria: 1) provide ongoing psychosocial support to medication for opioid use disorder patients (e.g., intake sessions, individual counseling, and/or group counseling sessions), and 2) have an active caseload * Exclusion criteria: Younger than 18 years of age, unable to provide informed consent * Persons on Medication for Opioid Use Disorder \[Not recruited, via electronic medical records only\] * Inclusion criteria: must be newly initiated on medication for opioid use disorders (within the past 30 days) and have concurrent stimulant use (indicated by self-report of past 30-day stimulant use or positive toxicology screen within 30 days). * Exclusion criteria: Younger than 18 years of age, Does not have electronic medical records
Contact & Investigator
Sara Becker
PRINCIPAL INVESTIGATOR
Northwestern University
Frequently Asked Questions
Who can join the NCT05702021 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stimulant Use (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05702021 currently recruiting?
Yes, NCT05702021 is actively recruiting participants. Contact the research team at Sara.becker@northwestern.edu for enrollment information.
Where is the NCT05702021 trial being conducted?
This trial is being conducted at Chicago, United States, Chicago, United States, Chicago, United States, Chicago, United States and 5 additional locations.
Who is sponsoring the NCT05702021 clinical trial?
NCT05702021 is sponsored by Northwestern University. The principal investigator is Sara Becker at Northwestern University. The trial plans to enroll 76 participants.